Snyder Capital Management L P Ligand Pharmaceuticals Inc Transaction History

Snyder Capital Management L P

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$74.52 - $117.06 $11.2 Million - $17.6 Million	-150,376 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$94.99 - $151.56 $346,713 - $553,194	-3,650 Reduced 2.37%	150,376 $16.9 Million
Q4 2021 Feb 14, 2022	BUY	$127.69 - $165.85 $3.46 Million - $4.49 Million	27,085 Added 21.34%	154,026 $23.8 Million
Q3 2021 Nov 15, 2021	SELL	$102.33 - $144.73 $122,693 - $173,531	-1,199 Reduced 0.94%	126,941 $17.7 Million
Q2 2021 Aug 16, 2021	BUY	$113.03 - $155.64 $5.38 Million - $7.41 Million	47,640 Added 59.18%	128,140 $16.8 Million
Q1 2021 May 17, 2021	SELL	$99.52 - $215.83 $10.7 Million - $23.3 Million	-107,806 Reduced 57.25%	80,500 $12.3 Million
Q4 2020 Feb 16, 2021	BUY	$80.55 - $106.05 $1.24 Million - $1.63 Million	15,400 Added 8.91%	188,306 $18.7 Million
Q3 2020 Nov 13, 2020	SELL	$89.56 - $126.72 $20,240 - $28,638	-226 Reduced 0.13%	172,906 $16.5 Million
Q2 2020 Aug 14, 2020	BUY	$68.28 - $123.65 $124,064 - $224,672	1,817 Added 1.06%	173,132 $19.4 Million
Q1 2020 May 15, 2020	BUY	$63.37 - $107.88 $10.9 Million - $18.5 Million	171,315 New	171,315 $12.5 Million

257

18.2M

26.8K

9.3K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $2.01B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of Snyder Capital Management L P, based on Form 13F filings with the SEC.

Stay updated on Snyder Capital Management L P with notifications on news.